Jefferies Sees Failure of Phase 3 BRAVO Study as a Positive for Biogen (BIIB)
Tweet Send to a Friend
Jefferies is maintaining its Buy rating and $124 price target on shares of Biogen (NASDAQ: BIIB) following the company's announcement ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
